Stockscreener 앱 받기
0.97
3.92%
-0.0396
Estrella Immunopharma Inc 주식(ESLA)의 최신 뉴스
Estrella Immunopharma’s (ESLA) “Buy” Rating Reaffirmed at D. Boral Capital - Defense World
Estrella Immunopharma, Inc. (ESLA) Doses First Patient in Higher-Dose Cohort of EB103 Phase I/II Trial - Yahoo
ESLA Stock Rating and Price Target Maintained by D. Boral Capita - GuruFocus
Estrella Immunopharma, Inc. Initiates Second Cohort and Doses First Patient in STARLIGHT-1 Trial of EB103 in Advanced B-Cell Non-Hodgkin's Lymphomas - marketscreener.com
Estrella Immunopharma Advances STARLIGHT-1 Clinical Trial - TipRanks
Estrella Immunopharma Initiates Second Cohort and Doses First Patient in STARLIGHT-1 Trial of EB103 in Advanced B-Cell Non-Hodgkin’s Lymphomas - BioSpace
ESLA Stock Rating and Price Target Maintained by D. Boral Capital | ESLA Stock News - GuruFocus
Estrella Immunopharma Initiates Second Cohort and Doses First Patient in STARLIGHT-1 Trial of EB103 in Advanced B-Cell Non-Hodgkin's Lymphomas - marketscreener.com
Estrella Immunopharma (ESLA) Advances in Phase I/II STARLIGHT-1 Trial | ESLA Stock News - GuruFocus
Geode Capital Management LLC Acquires 16,862 Shares of Estrella Immunopharma, Inc. (NASDAQ:ESLA) - Defense World
ESLA Stock: A Voyage Through Estrella Immunopharma Inc’s Finances - investchronicle.com
A stock that deserves closer examination: Estrella Immunopharma Inc (ESLA) - uspostnews.com
Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Buy Rating With a Price Target of $14.00 From CB Capital Partners - BioSpace
Estrella Immunopharma completes first dose cohort in STARLIGHT trial - Yahoo Finance
Sector Update: Health Care -February 21, 2025 at 03:42 pm EST - Marketscreener.com
Estrella Immunopharma Completes First Dose Group in Non-Hodgkin Lymphoma Study - Marketscreener.com
Estrella Immunopharma Completes First Dose Cohort In Starlight-1 Trial And Receives Approval To Initiate Higher Dose Cohort - Marketscreener.com
Estrella Immunopharma Completes First Dose Cohort in STARLIGHT-1 Trial and Receives Approval to Initiate Higher Dose Cohort - The Bakersfield Californian
Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) Receives Buy Rating with a 12-Month Price Target of $16.00 from D. Boral Capital - 01net
Estrella Immunopharma (NASDAQ:ESLA) Now Covered by Analysts at D. Boral Capital - Defense World
This aTyr Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
Estrella Immunopharma regains Nasdaq compliance - Investing.com
Tonix Pharmaceuticals (NASDAQ:TNXP) Stock Quotes, Forecast and News Summary - Benzinga
vTv Therapeutics (NASDAQ:VTVT) Stock Quotes, Forecast and News Summary - Benzinga
Estrella Immunopharma extends stock sale agreement with White Lion By Investing.com - Investing.com Canada
Estrella Immunopharma faces Nasdaq delisting over equity shortfall - Investing.com India
Spotlight On US Penny Stocks: Estrella Immunopharma And Two Others To Consider - Simply Wall St
Eureka Therapeutics Tackling Advanced Hepatocellular Carcinoma With T-Cell Therapy ECT204 in Phase 1/2 ARYA-3 Clinical Trial - CGTLive™
Estrella Immunopharma Appoints Dr. Cheng Liu as CEO - TipRanks
Tesla stock hits 52-week low at $0.75 amid market challenges - Investing.com
Around the Helix: Cell and Gene Therapy Company Updates – October 9, 2024 - CGTLive™
First Patient Dosed Achieves Complete Response in Estrella Immunopharma’s Trial for CD19-Targeted T-cell Therapy EB103 in B-Cell Lymphomas - CGTLive®
Estrella Immunopharma Achieves Complete Response in First Patient Treated with CD19- Redirected ARTEMIS® T-cells - BioSpace
Estrella Immunopharma Announces Appointment of Hong Zhang as Chairperson and Board Member - Business Wire
Estrella Immunopharma’s Trial for CD19-Targeted T-cell Therapy EB103 in B-Cell Lymphomas Doses First Patient - CGTLive®
Wall Street today: US stocks trade higher after promising inflation data raises Fed rate cut bets; 3M Co. gains 18.99% - Mint
OS Therapies (AMEX:OSTX) Stock Quotes, Forecast and News Summary - Benzinga
Estrella Immunopharma streamlines operations with subsidiary merger - Investing.com India
Laura Franco - Mintz
Next Big Thing: 3 Biotech Stocks to Watch for Groundbreaking Advances - InvestorPlace
Excision Seeks to Suppress HIV Viral Replication With EBT-101 CRISPR Gene Therapy - CGTLive™
Direct Biologics’ Phase 1 Clinical Trial Seeks to Treat Crohn Disease With Extracellular Vesicles - CGTLive™
Tenaya's Phase 1b MyPeak-1 Trial is Testing the Waters in Gene Therapy for Hypertrophic Cardiomyopathy - CGTLive™
ESLAEstrella Immunopharma Latest Stock News & Market Updates - StockTitan
ESLA Stock Price and Chart — NASDAQ:ESLA - TradingView
Estrella Immunopharma nears completion of SPAC listing - Bamboo Works
Calidi Biotherapeutics (AMEX:CLDI) Stock Quotes, Forecast and News Summary - Benzinga
Estrella and TradeUP merge to become publicly traded company - Labiotech.eu
Manufacturing Stocks Investing - MarketBeat
PepGen (NASDAQ:PEPG) Stock Quotes, Forecast and News Summary - Benzinga
TradeUP Acquisition (UPTD) Stock Price, News & Analysis - MarketBeat
Aadi Bioscience (NASDAQ:AADI) Stock Quotes, Forecast and News Summary - Benzinga
Immuneering (NASDAQ:IMRX) Stock Quotes, Forecast and News Summary - Benzinga
Tempest Therapeutics (NASDAQ:TPST) Stock Quotes, Forecast and News Summary - Benzinga
Achilles Therapeutics (NASDAQ:ACHL) Stock Quotes, Forecast and News Summary - Benzinga
Lantern Pharma (NASDAQ:LTRN) Stock Quotes, Forecast and News Summary - Benzinga
OncoCyte (NASDAQ:OCX) Stock Quotes, Forecast and News Summary - Benzinga
1.76%
0.89%
자본화:
|
볼륨(24시간):